CCM
DFTX

Covington Capital Management’s Definium Therapeutics DFTX Stock Holding History

Covington Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
206
+199
+2,843% +$1.91K ﹤0.01% 1139
2022
Q2 		$0 Buy
+7
New +$89 ﹤0.01% 1147

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Covington Capital Management's DFTX Position: Q3 2022 in Review

Covington Capital Management increased its Definium Therapeutics (DFTX) stake by 2,843% in Q3 2022, buying an estimated $1.91K and bringing the position to 206 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Covington Capital Management first reported a position in DFTX in Q2 2022 and has held it in 2 quarters since. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Covington Capital Management held 206 shares of Definium Therapeutics worth $1K as of Q3 2022.
  • Covington Capital Management bought 199 Definium Therapeutics shares in Q3 2022, an estimated $1.91K.
  • Definium Therapeutics made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #1139 holding.
  • Covington Capital Management first reported a position in Definium Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.